<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778436</url>
  </required_header>
  <id_info>
    <org_study_id>LT7082-001</org_study_id>
    <nct_id>NCT04778436</nct_id>
  </id_info>
  <brief_title>Macula Evolution in Patients With AMD Taking Oral Food Supplementation</brief_title>
  <official_title>Macular Drusen Evolution in Patients With Intermediate Age-related Macular Degeneration (AMD) Taking Oral Food Supplementation: an Open-label,Single-arm Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LT7082-001 is an open-label, single-arm pilot study. Patients with intermediate age-related&#xD;
      macular degeneration (AMD) wil take T7082 during 12 months , an association of 4 food&#xD;
      supplementations .&#xD;
&#xD;
      The study objectives are to describe morphological changes and evolution of drusen in macula&#xD;
      after a 12-month of food supplementation and to assess the safety of T7082&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>an open-label, single-arm, pilot study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evolution of drusen in the macula</measure>
    <time_frame>2 months, 5 months 8 months and 12 months</time_frame>
    <description>Change from baseline in drusen region in 4 categories (disappearance, decrease, stable, increase) at 2, 5 and 6 months by Optical Coherence Tomography (OCT-SD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>morphological changes in the macula</measure>
    <time_frame>2 months, 5 months 8 months and 12 months</time_frame>
    <description>Presence and/or evolution of atrophic area (Yes/No) at 2, 5, 6 and 12 months assessed by autofluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse events (TEAE), Serious treatment-emergent adverse events (STEAE), Treatment-Emergent Adverse Reaction (TEAR)</measure>
    <time_frame>2 months, 5 months 8 months and 12 months</time_frame>
    <description>Frequency of TEAE,STEAE,TEAR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>T7082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After inclusion, the patients will consume an association of 4 food supplements including Nutrof Total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>T7082</intervention_name>
    <description>Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call</description>
    <arm_group_label>T7082</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated&#xD;
&#xD;
          -  Age ≥ 50 years old&#xD;
&#xD;
          -  At least one Eligible Eye, defined by following conditions :&#xD;
&#xD;
               1. Far Best Corrected Visual Acuity (BCVA) ≥ 75 ETDRS letters (or ≥ 20/32 Snellen&#xD;
                  equivalent)&#xD;
&#xD;
               2. At least one drusen with a minimal diameter of 125 µM assessed by SD-OCT /&#xD;
                  intermediate age-related macular degeneration&#xD;
&#xD;
               3. Macula sparing&#xD;
&#xD;
               4. Clear ocular media&#xD;
&#xD;
               5. Adequate pupillary dilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other macular disease such as epiretinal membrane or macular&#xD;
             telangiectasia.&#xD;
&#xD;
          -  Presence of any geographic atrophy including macular region&#xD;
&#xD;
          -  Any history of retina neovascularization&#xD;
&#xD;
          -  Macula or retinal diseases other than age-related macular degeneration&#xD;
&#xD;
          -  A concurrent ocular pathology that may contribute to vision loss (eg, choroidal&#xD;
             neovascularization, glaucoma, visually significant cataract, optic neuropathy, history&#xD;
             of retinal surgery) or interfere with acquisition of high-quality images&#xD;
&#xD;
          -  Ocular or periocular infections&#xD;
&#xD;
          -  Presence of congenital retinal pathologies that may impact data collection&#xD;
&#xD;
          -  Exudative AMD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wilfried Roquet</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

